TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LESCOL XL

FLUVASTATIN SODIUM
Cardiovascular Approved 2000-10-06
3
Indications
--
Phase 3 Trials
1
Priority Reviews
25
Years on Market

Details

Status
Prescription
First Approved
2000-10-06
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

Companies

Active Ingredient: FLUVASTATIN SODIUM

LESCOL XL Approval History

Loading approval history...

What LESCOL XL Treats

4 indications

LESCOL XL is approved for 4 conditions since its original approval in 2000. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Coronary Heart Disease
  • Coronary Atherosclerosis
  • Hyperlipidemia
  • Heterozygous Familial Hypercholesterolemia
Source: FDA Label

Drugs Similar to LESCOL XL

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

FLUVASTATIN SODIUM
FLUVASTATIN SODIUM
3 shared
Teva
Shared indications:
Coronary Heart DiseaseCoronary AtherosclerosisHeterozygous Familial Hypercholesterolemia
VYTORIN
EZETIMIBE
3 shared
Merck
Shared indications:
HyperlipidemiaHeterozygous Familial HypercholesterolemiaCoronary Heart Disease
ATORVALIQ
ATORVASTATIN CALCIUM
2 shared
CMP DEV LLC
Shared indications:
Coronary Heart DiseaseHeterozygous Familial Hypercholesterolemia
CADUET
AMLODIPINE BESYLATE
2 shared
PHARMACIA
Shared indications:
HyperlipidemiaHeterozygous Familial Hypercholesterolemia
CRESTOR
ROSUVASTATIN CALCIUM
2 shared
AstraZeneca
Shared indications:
HyperlipidemiaHeterozygous Familial Hypercholesterolemia
FLOLIPID
SIMVASTATIN
2 shared
SALERNO PHARMS
Shared indications:
Coronary Heart DiseaseHeterozygous Familial Hypercholesterolemia
LIPITOR
ATORVASTATIN CALCIUM
2 shared
UPJOHN
Shared indications:
Coronary Heart DiseaseHeterozygous Familial Hypercholesterolemia
LOVASTATIN
LOVASTATIN
2 shared
COREPHARMA
Shared indications:
Coronary Heart DiseaseCoronary Atherosclerosis
ROSUVASTATIN CALCIUM
ROSUVASTATIN CALCIUM
2 shared
ZHEJIANG JINGXIN
Shared indications:
HyperlipidemiaHeterozygous Familial Hypercholesterolemia
SIMVASTATIN
SIMVASTATIN
2 shared
RISING
Shared indications:
Coronary Heart DiseaseHeterozygous Familial Hypercholesterolemia
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM
AMLODIPINE BESYLATE
1 shared
Viatris
Shared indications:
Hyperlipidemia
FENOFIBRIC ACID
CHOLINE FENOFIBRATE
1 shared
Aurobindo Pharma
Shared indications:
Hyperlipidemia
LEQVIO
INCLISIRAN SODIUM
1 shared
Novartis
Shared indications:
Heterozygous Familial Hypercholesterolemia
LEROCHOL
LERODALCIBEP-LIGA
1 shared
LIB THERAPEUTICS, INC.
Shared indications:
Heterozygous Familial Hypercholesterolemia
LIVALO
PITAVASTATIN CALCIUM
1 shared
KOWA CO
Shared indications:
Heterozygous Familial Hypercholesterolemia
LYPQOZET
ATORVASTATIN CALCIUM
1 shared
PHARMOBEDIENT
Shared indications:
Heterozygous Familial Hypercholesterolemia
NEXLETOL
BEMPEDOIC ACID
1 shared
ESPERION THERAPS INC
Shared indications:
Heterozygous Familial Hypercholesterolemia
NEXLIZET
BEMPEDOIC ACID
1 shared
ESPERION THERAPS INC
Shared indications:
Heterozygous Familial Hypercholesterolemia
NIACOR
NIACIN
1 shared
AVONDALE PHARMS
Shared indications:
Hyperlipidemia
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE
PHENTERMINE HYDROCHLORIDE
1 shared
Dr. Reddy's
Shared indications:
Hyperlipidemia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LESCOL XL FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

LESCOL XL is indicated: • To reduce the risk of undergoing coronary revascularization procedures and slow the progression of coronary atherosclerosis in adults with clinically evident coronary heart disease. • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in adults and pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH) who require 80 mg of fluvastatin daily. LESCOL XL is indicated : • To reduce the risk of undergoing coronary revasculariz...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.